The IPO market was in full swing this past week as 16 IPOs and six SPACs went public. The IPO pipeline cooled down with just one IPO and nine SPACs submitting initial filings. The largest deal of the week, Lyell Immunopharma (LYEL)...read more
Century Therapeutics, a preclinical biotech developing allogenic stem cell treatments for multiple cancers, raised $211 million by offering 10.6 million shares at $20, the high end of the range of $18 to $20. Century Therapeutics is developing an allogenic stem...read more
Century Therapeutics, a preclinical biotech developing allogenic stem cell treatments for multiple cancers, announced terms for its IPO on Monday. The Philadelphia, PA-based company plans to raise $200 million by offering 10.6 million shares at a price...read more
Updated Monday, 6/14. 15 IPOs are currently slated to raise $2.5 billion in the week ahead, led by a preclinical biotech being valued at $4.7 billion. The largest deal of the week, Lyell Immunopharma (LYEL) plans to raise...read more
US IPO Weekly Recap: IPO market in full swing as biotechs lead a 16 IPO week
The IPO market was in full swing this past week as 16 IPOs and six SPACs went public. The IPO pipeline cooled down with just one IPO and nine SPACs submitting initial filings. The largest deal of the week, Lyell Immunopharma (LYEL)...read more
Preclinical stem cell biotech Century Therapeutics prices IPO at $20 high end
Century Therapeutics, a preclinical biotech developing allogenic stem cell treatments for multiple cancers, raised $211 million by offering 10.6 million shares at $20, the high end of the range of $18 to $20. Century Therapeutics is developing an allogenic stem...read more
Preclinical stem cell biotech Century Therapeutics sets terms for $200 million IPO
Century Therapeutics, a preclinical biotech developing allogenic stem cell treatments for multiple cancers, announced terms for its IPO on Monday. The Philadelphia, PA-based company plans to raise $200 million by offering 10.6 million shares at a price...read more
US IPO Week Ahead: Biotechs and software lead a 15 IPO week
Updated Monday, 6/14. 15 IPOs are currently slated to raise $2.5 billion in the week ahead, led by a preclinical biotech being valued at $4.7 billion. The largest deal of the week, Lyell Immunopharma (LYEL) plans to raise...read more